Brief: Ac Immune Progress Update On Phase 2 Active Immunotherapy Clinical Pipeline
03/01/2024 13:17
Jan 3 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE PROGRESS UPDATE ON PHASE 2 ACTIVE IMMUNOTHERAPY
CLINICAL PIPELINE FOR ALZHEIMER'S AND PARKINSON DISEASES
* FOLLOWING DATA SAFETY MONITORING BOARD REVIEW, NO SAFETY
CONCERNS HAVE BEEN RAISED TO DATE PHASE FOR 1B/2 TRIAL OF
ACI-24.060
Source text for Eikon: ID:nGNXcg5g8v
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health